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Abstract. this study aimed to assess the effect on solid tumors 
of mild temperature hyperthermia (mth) combined with 
hexamethylenetetramine (hmta) or tirapazamine (tpZ). 
Squamous cell carcinoma (Scc Vii) tumor-bearing mice were 
continuously administered 5-bromo-2'-deoxyuridine (Brdu) to 
label intratumor proliferating (p) cells. mice received hmta or 
tpZ through intraperitoneal single or subcutaneous continuous 
administration, with or without MTH (40˚C, 60 min), followed 
or not by γ-ray irradiation or cisplatin treatment. after hmta or 
tpZ administration without γ-ray irradiation or cisplatin treat-
ment, immediately after γ-ray irradiation, or 1 h after cisplatin 
treatment, the response of quiescent (Q) cells was assessed in 
terms of micronucleus frequency using immunofluorescence 
staining for Brdu. the response of the total (p + Q) tumor cells 
was determined based on a comparison with non-Brdu-treated 
tumors. Without mth, hmta and tpZ had a nearly equal radi-
osensitizing and cisplatin sensitivity-enhancing effect on both 
total and Q cells. With mth, radio- and cisplatin-sensitizing 
effects by hmta were reduced, particularly in the Q cells. in 
contrast, the enhancing effects of tpZ were increased, particu-
larly in the Q cells. continuous administration of hmta and 
tpZ resulted in higher radio- and cisplatin-sensitizing effects 
than intraperitoneal single administration. in terms of tumor 
cytotoxicity as a whole, including Q cells, the administra-
tion of γ-ray irradiation or cisplatin treatment combined with 
continuous hmta administration is promising, taking into 
account the clinical use of hmta. however, mth should not 
be combined with hmta administration.
Introduction
hyperthermia is a heat treatment that directly targets cancer 
cells or the environment surrounding them (1). according to the 
tenets of hyperthermic oncology, significant tumor cell killing 
could theoretically be achieved if cells or tissues were heated 
to over 42˚C for 1 h or more (2). It is speculated that such heat 
treatment would induce radio- and chemosensitization, in part 
by inhibiting dna damage repair (1). however, clinical experi-
ence over the past 25 years has shown that it is not possible to 
routinely achieve thermal doses of over 42˚C for 1 h or more. 
it is now known that, during typical hyperthermia treatments 
with currently available heating technologies (except for 
thermal ablation), cytotoxic temperatures are only achieved in 
small sub-volumes of tumors (3). meanwhile, until recently the 
effects of mild temperature hyperthermia (MTH) (39-42˚C for 
1-2 h) on tissue have largely been ignored. however, mth has 
subtle effects, including heat-mediated tumor reoxygenation 
(4) and the inhibition of sublethal and potentially lethal damage 
repair (5), which provide a very strong rationale for using 
mth in combination with radiotherapy. in addition, the physi-
ological and cellular effects of mth can improve the delivery 
of drug vehicles (6), activate promoters for heat-mediated gene 
therapy (7) and increase immune response to tumors through 
a variety of mechanisms (8). indeed, mth has been reported 
to increase the response of tumors, in particular of quiescent 
(Q)-cell populations, to radiation or chemotherapeutic agents, 
in part by improving oxygenation through an increase in tumor 
blood flow (9).
tumor hypoxia results from limited oxygen diffusion 
(chronic hypoxia) or limited perfusion (acute hypoxia, transient 
hypoxia or ischemic hypoxia) (10). chronically hypoxic tumor 
cells existing at the rim of the oxygen diffusion distance are 
killed by just a single administration of tirapazamine (tpZ), a 
lead compound identified in the development of a bioreductive 
hypoxic cytotoxin (Fig. 1), while acutely hypoxic tumor cells 
occurring sporadically throughout solid tumors are killed by 
long-term continuous administration of tpZ. therefore, the 
long-term continuous administration of tpZ is capable of 
killing both chronically and acutely hypoxic tumor cells (9).
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although tpZ has enhanced some standard clinical regi-
mens, the results are variable and, with certain combinations, 
toxicity is enhanced (11). neutropenia is commonly reported, 
but usually within a tolerable range. the most frequent 
non-hematological toxicities reported are nausea, vomiting, 
diarrhea and skin rash. two additional unusual toxicities are 
reversible deafness and muscle cramping (11). according to a 
recently reported in vivo animal study, the addition of tpZ to 
cisplatin/radiotherapy treatment caused a significant increase 
in toxicity, in particular to the heart, liver, kidney and stomach, 
and had only moderate effects on the tumor (12). as a result, 
TPZ has exhibited no clear beneficial effects compared to 
conventional drugs in clinical trials conducted to date.
Formaldehyde preserves or fixes tissues or cells by 
irreversibly crosslinking primary amine groups in proteins 
with other nearby nitrogen atoms in protein or dna through 
a -ch2- linkage (13). hexamethylenetetramine (hmta) 
(Fig. 1), an acid-dependent formaldehyde donor, has been used 
as an antiseptic for urinary tract infections and is characterized 
as non-carcinogenic in animals (13). under hypoxic conditions 
in solid tumors, pyruvate generated by glycolysis creates a low 
ph environment that produces formaldehyde through the dis-
sociation of hmta (14).
excepting surgical resection, chemotherapy using 
cis-diamminedichloroplatinum (cisplatin) and radiotherapy 
are the most frequently employed anticancer therapeutic 
modalities applied in the clinical setting. Based on clinical 
experience and using a previously developed method for 
selectively detecting the response of Q cell populations 
within solid tumors (15), the combined effect of mth with 
γ-ray irradiation or cisplatin treatment in combination with 
or without hmta or tpZ administration was evaluated. in 
addition, the efficacy of continuous administration of HMTA 
or tpZ versus single injection was examined.
Materials and methods
Mice and tumors. Scc Vii squamous cell carcinomas 
(department of radiotherapy, Kyoto university) derived from 
c3h/he mice were maintained in vitro in eagle's minimum 
essential medium supplemented with 12.5% fetal bovine serum. 
the cells (1.0x105) were inoculated subcutaneously into the 
left hind legs of 8- to 11-week-old syngeneic female c3h/he 
mice (Japan animal co., ltd., osaka, Japan). after 14 days, 
tumors with a diameter of ~1 cm were selected for use in the 
experiments. the body weight of the tumor-bearing mice was 
22.1±2.3 g (mean ± Sd). mice were handled according to the 
recommendations for handling of laboratory animals for 
Biomedical research, compiled by the committee on Safety 
and ethical handling regulations for laboratory animal 
experiments of Kyoto university. the p53 of the Scc Vii 
tumor cells was wild-type (15).
Labeling with 5-bromo-2'-deoxyuridine. nine days after 
inoculation, mini-osmotic pumps (durect corporation, 
cupertino, ca, uSa) containing 5-bromo-2'-deoxyuridine 
(Brdu) dissolved in physiological saline (250 mg/ml) were 
implanted subcutaneously for 5 days to label all proliferating 
(p)-cells. the percentage of labeled cells in the Scc Vii 
tumors after continuous labeling with Brdu reached a plateau 
at 55.3±4.5%. intratumor cells not incorporating Brdu after 
continuous labeling were determined to be Q cells.
Treatment. after labeling with Brdu, tpZ and hmta 
dissolved in physiological saline were administered at doses 
of 0.224 mmol/kg or 28.5 mmol/kg, respectively, by single 
intraperitoneal injection or by continuous administration for 
24 h by means of subcutaneously implanted mini-osmotic 
pumps. MTH (40˚C, 60 min) was initiated immediately after 
single intraperitoneal injection or was performed during the 
continuous administration, immediately before γ-ray irradia-
tion or cisplatin treatment. not all tumors received mth prior 
to γ-ray irradiation or cisplatin treatment.
to detect the radiosensitizing effects of tpZ or hmta, 
whole body irradiation with γ-rays was performed at a dose 
of 4 or 20 gy using a cobalt-60 γ-ray irradiator at a dose rate 
of ~2.5 gy/min. cisplatin was intraperitoneally administered 
at a dose of 0.5 ld50 (the dose required to kill 50% of cells, 
ld50=17.7 mg/kg) to detect the cisplatin sensitivity-enhancing 
effects of tpZ or hmta. cytotoxicity was assessed in terms 
of cell survival and induced micronucleus (mn) frequency 
following the intraperitoneal or continuous administration of 
tpZ or hmta alone at the above doses (16).
For mth, the tumors grown in the left hind legs of mice 
were heated at 40˚C for 60 min by immersion of the tumor-
bearing foot in a water bath as follows: the mouse was held in 
a specially constructed device with the tail and right leg firmly 
fixed with adhesive tape. The left tumor-bearing leg was pulled 
down by a special sinker (~45 g) affixed to the skin of the toe 
with Superglue (arone-arufa, Konishi co., osaka, Japan). the 
mouse was placed in a circulating water bath maintained at the 
desired temperature, and was air-cooled during the heat treat-
ment (17). temperatures at the tumor center equilibrated within 
3-4 min of immersion in the water bath and remained 0.2-0.3˚C 
below bath temperature. the water bath temperature was there-
fore maintained at 0.3˚C above the desired tumor temperature.
in mice receiving hmta or tpZ treatment alone, the 
implanted tumors were excised 1 h after the single intraperi-
toneal injection or after the 24-h continuous subcutaneous 
infusion. in mice receiving the combination of each drug with 
γ-ray irradiation, implanted tumors were excised immediately 
Figure 1. chemical structure of hexamethylenetetramine (hmta) and 
tirapazamine (tpZ).
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after irradiation. For the combination with cisplatin treatment, 
implanted tumors were excised 1 h after the administration of 
cisplatin. 
the above-mentioned sequences and the timing of each 
treatment were based on data obtained from preliminary 
experiments. procedures were appropriate and were carried 
out successfully (9,16).
Immunofluorescence staining of BrdU-labeled cells and 
micronucleus assay. tumors excised from the mice adminis-
tered Brdu were minced and trypsinized with 0.05% trypsin 
and 0.02% ethylenediamine-tetraacetic acid (edta) in 
phosphate-buffered saline (PBS) at 37˚C for 15 min. Tumor cell 
suspensions were incubated for 72 h in tissue culture dishes 
containing complete medium and 1.0 µg/ml of cytochalasin-B 
in order to inhibit cytokinesis while allowing nuclear division. 
the cultures were subsequently trypsinized and the cell sus-
pensions were fixed. After the centrifugation of the fixed cell 
suspensions, the cell pellet was resuspended with cold carnoy's 
fixative (ethanol:acetic acid, 3:1 volume). The suspension was 
then placed on a glass microscope slide and the sample was 
dried at room temperature. the slides were treated with 2 m 
hydrochloric acid for 60 min at room temperature to dissociate 
the histones and to partially denature the dna, and were then 
immersed in borax-borate buffer (ph 8.5) to neutralize the acid. 
Brdu-labeled tumor cells were detected by indirect immuno-
fluorescence staining using monoclonal anti-BrdU antibody 
(Becton Dickinson, San Jose, CA, USA) and fluorescein isothi-
ocyanate (Fitc)-conjugated antimouse igg antibody (Sigma, 
St. louis, mo, uSa). to observe the double staining of tumor 
cells with green-emitting Fitc and red-emitting propidium 
iodide (pi), cells on the slides were treated with pi (2 µg/ml in 
PBS) and monitored under a fluorescence microscope.
Since cytochalasin-B inhibits cytokinesis while allowing 
nuclear division, cultured tumor cells were transformed into 
binuclear cells after the first cell division. When cell division 
is disrupted or chromosomes have been broken or damaged 
by chemicals or radiation, the distribution of genetic mate-
rial between the two-daughter nuclei during cell division is 
affected, and pieces or entire chromosomes fail to be included 
in either of the two-daughter nuclei. genetic material that is not 
incorporated into a new nucleus forms its own ʻmicronucleus’. 
micronucleus (mn) frequency in cells not labeled with Brdu 
was examined by counting the micronuclei in the binuclear 
cells that showed only red fluorescence. The MN frequency 
was defined as the ratio of the number of micronuclei in the 
binuclear cells to the total number of binuclear cells observed 
(15). mn frequency may also be used to detect sensitivity to 
chemotherapeutic agents (15). 
the ratios obtained in tumors not pre-treated with Brdu 
revealed the mn frequency at all phases in the total (p + Q) 
tumor cell population. more than 400 (444±31) binuclear cells 
were counted to determine mn frequency. the mn frequen-
cies in control cells receiving absolutely no treatment were 
0.056±0.005 and 0.081±0.011, with respect to the total tumor 
and Q cell populations in the Scc Vii tumors. For baseline 
correction, the induced mn frequency (the mn frequency 
of the treated tumors minus that of the non-treated control 
tumors) was used to exclude the mn frequency in control cells 
receiving absolutely no treatment.
Clonogenic cell survival assay. the clonogenic cell survival 
assay was also performed in the mice not pre-treated with 
Brdu using an in vivo-in vitro assay method. tumors were 
excised from the mice, minced and disaggregated by stirring 
for 20 min at 37˚C in PBS containing 0.05% trypsin and 0.02% 
edta. through these procedures, single tumor cell suspen-
sions were obtained from the whole tumor. the cell yield was 
(4.5±1.1)x107/g tumor weight. appropriate numbers of viable 
tumor cells from the single cell suspension were plated on 60 
or 100-mm tissue culture dishes. after 12 days, the colonies 
were fixed with ethanol, stained with Giemsa and counted. 
Plating efficiency under the no treatment control condition was 
52.0±4.5%.
the sensitivity of Q cells was assessed in terms of the mn 
frequency using immunofluorescence staining for BrdU, while 
the sensitivity of the total (p + Q) tumor cells was determined 
based on a comparison with the non-Brdu-treated tumors 
based on mn frequency and clonogenic cell survival.
Four mice were used to assess each set of conditions, and 
each experiment was repeated at least twice. to examine the 
differences between pairs of values, the Student's t-test was 
used when variances between the two groups were assumed 
to be equal; otherwise, Welch's t-test was used. p-values were 
determined by two-sided tests.
Results
changes in the clonogenic cell surviving fraction of the total 
tumor cell population (upper panels), as well as changes in the 
induced mn frequencies of the total and Q cell populations 
(lower panels) following intraperitoneal single or subcutaneous 
Figure 2. changes in the clonogenic cell surviving fraction of the total tumor 
cell population (upper panels) and the induced micronucleus frequencies of 
the total and quiescent (Q)-cell populations (lower panels) following intraperi-
toneal (i.p.) single or subcutaneous 24-h continuous (cont.) administration of 
tirapazamine (tpZ) (left panels) or hexamethylenetetramine (hmta) (right 
panels), in combination with or without mild temperature hyperthermia (mth) 
(40˚C, 60 min). Assays were performed 1 h after i.p. single administration or 
after the 24-h cont. administration. Bars represent the Sd.
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24-h continuous administration of tpZ (left panels) or hmta 
(right panels) in combination with or without MTH (40˚C, 
60 min) are shown in Fig. 2. 
under all conditions, the sensitivity of the Q cells was 
significantly higher than that of the total cells, regardless of 
whether tpZ or hmta was used (p<0.05). concerning both 
TPZ and HMTA, sensitivity was significantly higher with 
continuous administration than with intraperitoneal single 
administration (p<0.05). Sensitivity to tpZ was enhanced by 
the combination with mth, whether tpZ was administered 
by single or continuous administration. in contrast, sensitivity 
to hmta was decreased in combination with mth.
changes in the clonogenic cell surviving fraction of the 
total tumor cell population (upper panels) and the induced mn 
frequencies of the total or Q cell populations (lower panels) 
immediately after γ-ray irradiation in combination with or 
without pre-irradiation intraperitoneal single or subcutaneous 
continuous administration of tpZ (left panels) or hmta 
(right panels) in further combination with or without mth, 
are shown in Figs. 3 (4 gy irradiation dose) and 4 (20 gy 
irradiation dose). 
concerning both tpZ and hmta, subcutaneous con-
tinuous administration compared with intraperitoneal single 
administration induced significantly higher sensitivity to 
γ-rays at doses of both 4 and 20 gy in the total and the Q 
cells (p<0.05). regardless of whether tpZ was administered 
by single or continuous administration, with γ-ray irradiation 
at doses of 4 and 20 gy, the combination with mth enhanced 
γ-ray sensitivity, especially in the Q cells. in contrast, γ-ray 
sensitivity was reduced by hmta in combination with mth, 
especially in the Q cells.
changes in the clonogenic cell surviving fraction of the 
total tumor cell populations (upper panels) and the induced mn 
frequencies of the total or Q cell populations (lower panels) 
1 h after intraperitoneal single administration of cisplatin in 
combination with or without pre-treatment intraperitoneal 
single or subcutaneous continuous administration of tpZ (left 
panels) or hmta (right panels) in further combination with or 
without mth are shown in Fig. 5. 
regardless of whether tpZ or hmta was used, subcuta-
neous continuous administration induced significantly higher 
sensitivity to cisplatin in both the total and Q cells compared 
to intraperitoneal single administration (p<0.05). concerning 
both single or continuous administration of tpZ, the combi-
nation with mth enhanced cisplatin sensitivity, especially in 
the Q cells. in contrast, cisplatin sensitivity in combination 
with hmta was reduced in further combination with mth, 
especially in the Q cells.
Without mth, the enhancing effects of continuous admin-
istration compared with intraperitoneal single administration 
were more marked in total cells than in Q cells, regardless of 
whether hmta or tpZ was administered in combination with 
γ-ray irradiation or cisplatin treatment. in cells treated with 
tpZ or hmta alone, both drugs had nearly the same cytotoxic 
effect in terms of cell survival and induced mn frequency 
when administered by intraperitoneal single administration.
Figure 3. changes in the clonogenic cell surviving fraction of the total tumor 
cell population (upper panels) and the induced micronucleus frequencies of the 
total or quiescent (Q)-cell populations (lower panels) immediately after γ-ray 
irradiation at a dose of 4 gy, in combination with or without pre-irradiation 
intraperitoneal (i.p.) single or subcutaneous continuous (cont.) administration 
of tirapazamine (tpZ) (0.224 mmol/kg; left panels) or hexamethylenete-
tramine (hmta) (28.5 mmol/kg; right panels) in further combination with or 
without mild temperature hyperthermia (MTH) (40˚C, 60 min). Assays were 
performed immediately after irradiation, 1 h after i.p. single administration or 
after the 24-h cont. administration. Bars represent the Sd.
Figure 4. changes in the clonogenic cell surviving fraction of the total tumor 
cell population (upper panels) and the induced micronucleus frequencies 
of the total or quiescent (Q)-cell populations (lower panels) immediately 
after γ-ray irradiation at a dose of 20 gy, in combination with or without 
pre-irradiation intraperitoneal (i.p.) single or subcutaneous continuous 
(cont.) administration of tirapazamine (tpZ) (0.224 mmol/kg; left panels) 
or hexamethylenetetramine (hmta) (28.5 mmol/kg; right panels) in further 
combination with or without mild temperature hyperthermia (MTH) (40˚C, 
60 min). assays were performed immediately after irradiation. Bars represent 
the Sd.
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Discussion
Formaldehyde is a naturally occurring biological compound 
present in all tissues, cells and bodily fluids (13). It functions 
as a key intermediate in the ʻone-carbon pool’ used for the 
biosynthesis of purines, thymidine and some amino acids. it 
is usually rapidly metabolized by reduction, oxidation and 
reduced glutathione-dependent pathways (13). however, satu-
ration in formaldehyde metabolism leads to dna damage. it 
has been shown that cells exposed to formaldehyde exhibit, as 
a major form of dna damage, dna-protein crosslinks (18). in 
a limited oxygen environment, pyruvate generated by glycolysis 
in the cell cytoplasm is preferentially converted into lactic acid 
by lactate dehydrogenase, which creates a low ph environment 
(ph 6.4-6.8) (19). Furthermore, through the Warburg effect, 
many cancer cells vigorously consume glucose and preferentially 
produce lactic acid, even in the presence of adequate oxygen 
(19). thus, due to the extracellular acidic conditions adjacent to 
solid tumors, an acid-dependent formaldehyde donor, hmta, 
dissociates to release formaldehyde into nearby tissues. 
hmta has been employed as an antiseptic for the treatment 
of urinary tract infections, and has been studied in patients 
with maxillofacial phelegmons and for use as a prophylactic 
agent against recurrent acute cystitis (13,14). hmta has been 
demonstrated to be well tolerated, even at doses of up to 5 g/kg/
day (14,20). Since hmta is known to hydrolyze under cellular 
conditions and to release 6 molecules of formaldehyde in a ph-
dependent manner (14), we examined hmta for its potential as 
a formaldehyde-releasing prodrug for damaging dna within 
a tumor cell. as shown in our previous report, γ-ray irradiation 
and cisplatin treatment combined with continuous hmta or 
tpZ administration is promising in terms of the tumor cell-
killing effect as a whole (including Q cells) (16).
the mn frequencies of cells from tumors treated with 
mth only showed that mth was not capable of inducing 
direct thermal cytotoxicity. it has also been reported that this 
level of mild heating cannot delay tumor growth or cause 
direct thermal radiosensitization (17). in a previous study, 
mth mainly oxygenated the chronically hypoxic fraction, 
though it had less of an impact than carbogen inhalation 
(15). moreover, it has been shown that cells intermediate in 
oxygenation are able to influence tumor response to radiation, 
and that such cells and hypoxic cell cytotoxins potentially 
constitute a significant proportion of solid tumors (21). Thus, 
it has been suggested that mth changes certain chronically 
hypoxic fractions to a level intermediate between fully oxy-
genated and hypoxic through an increase in tumor blood flow, 
and at the same time distributes higher doses of tpZ and kills 
cells at these intermediate oxygen tensions (21). indeed, mth 
has been demonstrated to induce an increase in tumor po2 
(4), particularly in the oxygenation of Q cell populations (15), 
resulting from an improvement in the supply of oxygen via 
an increase in tumor blood flow. MTH has also been shown 
to sensitize total cells and, in particular, Q cells to the toxicity 
of tpZ when combined with or without γ-ray irradiation and/
or cisplatin (15). the present study also demonstrated that the 
combination with mth is useful for enhancing tpZ toxicity 
in total cells and, in particular, Q cells, when combined with or 
without γ-ray irradiation or cisplatin treatment.
the Warburg effect refers to the observation that most 
cancer cells predominantly produce energy by glycolysis 
followed by lactic acid fermentation in the cytosol, rather 
than by oxidation of pyruvate in mitochondria like most 
normal cells (19). at present, the Warburg effect is thought 
to be i) the result of damage to the mitochondria in cancer, ii) 
an adaptation to low-oxygen environments within tumors, or 
iii) the result of cancer genes shutting down the mitochondria 
because they are involved in a cell apoptosis program that 
would otherwise kill cancerous cells (22). Since the use of 
mth can improve intratumor oxygen supply via an increase in 
tumor blood flow, the Warburg effect is suppressed with MTH 
treatment. thereby, the production of formaldehyde from 
hmta under acidic conditions is also suppressed, resulting in 
a decrease in the amount of dna-protein crosslink as a major 
form of dna damage through exposure to formaldehyde. thus, 
whether combined with or without γ-ray irradiation or cisplatin 
treatment, sensitivity to hmta was reduced in combination 
with mth in total and Q cells. this was particularly the case 
in Q cells, due to greater improvements in the oxygen supply 
through mth in the Q  compared to total cell population (15). 
Furthermore, whether γ-ray irradiation was administered at a 
dose of 4 or 20 gy, further combination with mth on the com-
bined effect of radiation with hmta or tpZ had nearly the same 
effect. this means that the effect of combination with mth is 
almost interchangeable, irrespective of radiation fraction size in 
fractionated radiotherapy. The findings observed in this study 
can be applied to fractionated radiotherapy with small fraction 
size, such as practically performed radiotherapy.
Figure 5. changes in the clonogenic cell surviving fraction of the total tumor 
cell populations (upper panels) and the induced micronucleus frequen-
cies of the total or quiescent (Q)-cell populations (lower panels) 1 h after 
intraperitoneal (i.p.) single administration of cisplatin (cis.) (8.85 mg/kg) 
in combination with or without pre-treatment i.p. single or subcutaneous 
continuous (cont.) administration of tirapazamine (tpZ) (0.224 mmol/kg; left 
panels) or hexamethylenetetramine (hmta) (28.5 mmol/kg; right panels) in 
further combination with or without mild temperature hyperthermia (mth) 
(40˚C, 60 min). Assays were performed 1 h after cisplatin treatment. Bars 
represent the Sd.
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it has previously been shown that total- and Q cell popula-
tions in Scc Vii tumors are rich in acutely and chronically 
hypoxic fractions, respectively (15). therefore, continuously 
administered hmta or tpZ was more cytotoxic to tumor 
cells in vivo than single intraperitoneal administration, since 
the sensitizing effect on the acutely hypoxia-rich total cell 
population was added to the effect had on the chronically 
hypoxia-rich Q cell population (9). this is why the enhancement 
observed with continuous administration compared to single 
administration was more marked in the total cell population 
than in Q cells.
the presence of Q cells is thought to be due, in part, to 
hypoxia and the depletion of nutrition in the tumor core. this 
is another consequence of poor vascular supply (23), and might 
promote the formation of micronuclei in Q tumor cells, even 
without any treatment. essentially, Q cells showed less sensi-
tivity to γ-ray irradiation and cisplatin treatment (15), which 
means more Q cells than p cells survive after conventional 
radiotherapy or chemotherapy. thus, the control of Q cells 
has a great impact on the outcome of anticancer treatment. 
as a result, conventional radiotherapy or chemotherapy in 
combination with hmta or tpZ, which in and of themselves 
have significantly more toxicity to Q cells than to the total cell 
population, is thought to be useful. taking into account that 
hmta has a history of clinical use as an antiseptic for urinary 
tract infections (13,14), it may have more potential than tpZ to 
be employed with conventional anticancer therapy. however, 
studies on the toxicity of hmta in normal tissue must still 
be carried out for safety assurance. in terms of the tumor 
cell-killing effect as a whole, including intratumor Q cell 
control, continuously administered hmta in combination 
with conventional radiotherapy and chemotherapy may be a 
promising treatment modality for refractory tumors due to its 
advantageous cytotoxic effects. however, hmta combined 
with mth should not be employed, due to a reduction in the 
radiosensitizing or chemotherapy sensitivity-enhancing effect 
observed when hmta is used as a combined agent in conven-
tional radiotherapy and chemotherapy.
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